Chadwick Mills

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, on its $120 million Series C.

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Cooley advised NGM Biopharmaceuticals (NGM Bio), a wholly owned subsidiary of NGM Bio Holdings and a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, on its $122 million Series A financing.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.